Immunoliposomal systems targeting primary effusion lymphoma: in vitro study. (September 2010)

• Record Type: Journal Article
• Authors: Ruozi, Barbara; Riva, Giovanni; Belletti, Daniela; Tosi, Giovanni; Barozzi, Patrizia; Luppi, Mario; Forni, Flavio; Vandelli, Maria Angela
• Is Part Of: Nanomedicine. Volume 5:Number 7(2010)
• Page Start: 1051
• Page End: 1064
• Publication Date: 2010-09
• Subjects: atomic force microscopy (phase image) -- cationic PEGylated anti-CD138 liposomes -- drug targeting -- monoclonal antibodies -- primary effusion lymphoma; Nanotechnology -- Periodicals; Medical technology -- Periodicals; Nanotechnology -- Therapeutic use -- Periodicals; 610.28
• DOI: 10.2217/nnm.10.83
• Languages: English
• ISSNs: 1743-5889

Abstract

Aims: To develop an appropriate liposomal formulation for gene delivery against primary effusion lymphoma (PEL), a herpesvirus HHV8-associated B-cell lymphoma.Materials & methods: Cationic, cationic PEGylated and cationic PEGylated anti-CD138 liposomes (ILp) linking a monoclonal antibody expressed on PEL cells were prepared by a thin layer evaporation method, followed by extrusion technique. The formulations were mixed with a model oligonucleotide to form the lipoplexes and tested on a BCBL-1 cell (a PEL cell line). The transfection efficiency was evaluated by flow cytometry and confocal laser scanning microscopy analysis.Results: Based on antigen–antibody interaction, ILp mediated a specific gene delivery as shown by a significant increase in the transfection rate and a localized internalization of the oligonucleotide, in comparison with cationic liposomes and cationic PEGylated liposomes.Conclusion: ILp could be proposed as effective carriers for oligonucleotide transfer in BCBL-1 cells. In vitro experimental results encourage us to further test the in vivo therapeutic potential of ILp for specific delivery of antitumoral agents.